Pfizer (PFIZER) Share Price Falls 3.49% Today as Large-Cap Pharma Stock Declines
- September 8, 2026
- Posted by: Harsh Piplani
- Category: News
Pfizer Share Price fell to Rs 4,434 on 08 September 2026, down 3.49% for the day, taking the company’s market capitalisation to Rs 21,107.32 crore. The supplied data confirms the decline, but it does not identify a company-specific catalyst behind the move.
Pfizer Share Price today opened at Rs 4,599.95, which was also the day’s high, and then fell to an intraday low of Rs 4,410 before trading near that lower band. That price path points to weakness through the session rather than a brief dip. Turnover stood at Rs 0.84 crore at the captured time.
For investors tracking the stock, the verified takeaways are clear: Pfizer was down on the day, it was trading below its long-term averages, and its valuation and profitability metrics need to be viewed against the Pharmaceuticals & Drugs industry benchmark before broader conclusions are drawn.
Pfizer (PFIZER) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 4,434 |
| Previous Close | Rs 4,594.25 |
| Today's Move | -Rs 160.25 (-3.49%) |
| Open | Rs 4,599.95 |
| High | Rs 4,599.95 |
| Low | Rs 4,410 |
| Turnover | Rs 0.84 crore |
| Market Capitalisation | Rs 21,107.32 crore |
| Market Cap Category | Large Cap |
Pfizer Share Price reflects a weak intraday structure, with the stock opening at Rs 4,599.95, exactly matching the day’s high, and then moving lower to Rs 4,410 before trading around Rs 4,434. That pattern suggests sellers controlled the session after the open.
Compared with the previous close of Rs 4,594.25, the stock was down Rs 160.25, or 3.49%, at the captured time. For a Large Cap company, that is a notable single-day move. The fact that the stock opened slightly above the previous close but could not hold that level adds context to the decline.
The intraday range between Rs 4,599.95 and Rs 4,410 shows meaningful price movement, while turnover of Rs 0.84 crore indicates activity around the move. The current price was also below the 50 DMA of Rs 4,823.59 and the 200 DMA of Rs 4,762.04, keeping the near-term trend under watch.
Pfizer (PFIZER) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 21,107.32 crore |
| P/E Ratio | 28.59x |
| P/B Ratio | 4.77x |
| ROE | 17.16% |
| ROCE | 23.39% |
| EPS | Rs 160.7 |
| Book Value Per Share | Rs 963.41 |
| Dividend Yield | 1.63% |
Pfizer’s fundamentals show a sizeable company with a market cap of Rs 21,107.32 crore. At the captured price, the stock traded at a P/E ratio of 28.59 and a P/B ratio of 4.77, figures that need to be judged against sector benchmarks rather than in isolation.
From a returns perspective, the company reported ROE of 17.16% and ROCE of 23.39%. EPS stood at Rs 160.7, book value per share was Rs 963.41, and dividend yield was 1.63%. Together, these numbers suggest that today’s fall is taking place in a stock with solid reported profitability metrics, even as market sentiment remained weak during the session.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 28.59x |
| Benchmark Median P/E | 32.52x |
| Benchmark Average P/E | 49x |
| Benchmark P/E Range | 3.35x to 654.07x |
| Company P/B Ratio | 4.77x |
| Benchmark Median P/B | 3x |
| Benchmark Average P/B | 4.41x |
| Company ROE | 17.16% |
| Benchmark Median ROE | 11.82% |
| Benchmark Average ROE | 11.12% |
| Company ROCE | 23.39% |
| Benchmark Median ROCE | 13.71% |
| Benchmark Average ROCE | 13.62% |
| Company Market Capitalisation | Rs 21,107.32 crore |
| Benchmark Median Market Cap | Rs 701.65 crore |
| Benchmark Average Market Cap | Rs 14,050.04 crore |
Pfizer operates in Healthcare, specifically the Pharmaceuticals & Drugs industry. The same-industry benchmark covers 201 companies and gives useful context for valuation and profitability.
The company’s P/E ratio of 28.59 is below the industry median of 32.52 and the average of 49. Its P/B ratio of 4.77, however, is above the industry median of 3 and slightly above the average of 4.41. So, on earnings multiple the stock looks below benchmark central levels, while on book-value multiple it sits above them.
Profitability compares more favourably. Pfizer’s ROE of 17.16% is above the industry median of 11.82% and average of 11.12, while ROCE of 23.39% is above the median of 13.71% and average of 13.62. In market-cap terms, Rs 21,107.32 crore is above both the industry median of Rs 701.65 crore and the average of Rs 14,050.04 crore.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,55,633.71 | 37.69 | 5.27 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,41,576.41 | 84.45 | 13.99 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,84,478.41 | 85.68 | 20.82 | 26.76 | 19.27 |
| Cipla | CIPLA | 1,11,888.39 | 33.46 | 3.21 | 11.83 | 16 |
| Zydus Lifesciences | ZYDUSLIFE | 1,11,820.18 | 25.53 | 4.27 | 19.69 | 21.39 |
Peer comparison adds another layer to the Pfizer Share Price move. Against Sun Pharmaceutical Industries, Pfizer trades at a lower P/E of 28.59 versus 37.69, while its ROE of 17.16% and ROCE of 23.39% are above Sun Pharma’s 14.85% and 19.11%. Sun Pharma, however, is far larger by market capitalisation.
Against Divi’s Laboratories and Torrent Pharmaceuticals, Pfizer looks cheaper on valuation, with those peers trading at P/E multiples of 84.45 and 85.68. Compared with Cipla, Pfizer has stronger return ratios than Cipla’s ROE of 11.83% and ROCE of 16. Zydus Lifesciences trades at a lower P/E of 25.53 and lower P/B of 4.27, while reporting ROE of 19.69% and ROCE of 21.39%.
The overall peer picture is balanced. Pfizer is smaller than several major pharma names in the comparison set, but its profitability remains competitive while its valuation is not the highest in the group.
Why Investors Are Watching Pfizer
- Notable one-day move: the stock declined 3.49%, or Rs 160.25, from the previous close of Rs 4,594.25 to Rs 4,434.
- Weak intraday structure: the session opened at Rs 4,599.95, which was also the high, before falling to Rs 4,410.
- Below key long-term averages: the current price is below the 50 DMA of Rs 4,823.59 and the 200 DMA of Rs 4,762.04.
- Profitability remains notable: ROE stands at 17.16% and ROCE at 23.39%, both above the supplied industry medians.
- Sector valuation context matters: its P/E of 28.59 is below the same-industry median of 32.52, while P/B of 4.77 is above the benchmark median of 3.
About Pfizer
Pfizer is classified within the Healthcare sector and the Pharmaceuticals & Drugs industry. Based on the supplied market data, it is a Large Cap listed company with a market capitalisation of Rs 21,107.32 crore, placing it above the same-industry median company size of Rs 701.65 crore.
This positioning matters because the stock is being assessed alongside some of the market’s most watched pharma counters. In the supplied benchmark of 201 companies, valuation, profitability and relative size all shape how investors interpret daily moves and longer-term positioning.
Track Pfizer Share Price on Univest
UsePfizer (PFIZER) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
Investors following Pfizer Share Price can use Univest to track live price moves, fundamental ratios, market capitalisation and sector comparisons in one place. That context can be useful when daily stock action turns active during the trading session.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Pfizer Share Price falling today?
Ans. Pfizer Share Price was down 3.49% at Rs 4,434 versus the previous close of Rs 4,594.25. The supplied data confirms the decline and intraday weakness, but it does not establish a company-specific catalyst behind the move.
What is Pfizer Share Price today?
Ans. Pfizer Share Price was Rs 4,434 at the captured time on 08 September 2026. The stock opened at Rs 4,599.95, touched a high of Rs 4,599.95 and a low of Rs 4,410 during the session.
What does Pfizer valuation look like right now?
Ans. Pfizer is trading at a P/E ratio of 28.59 and a P/B ratio of 4.77. Its P/E is below the same-industry median of 32.52, while its P/B is above the benchmark median of 3.
How profitable is Pfizer compared with the industry benchmark?
Ans. Pfizer reports ROE of 17.16% and ROCE of 23.39%. Both are above the Pharmaceuticals & Drugs industry medians of 11.82% for ROE and 13.71% for ROCE in the supplied benchmark set.
What is the market capitalisation of Pfizer?
Ans. The company’s market capitalisation stands at Rs 21,107.32 crore, classifying it as a Large Cap stock in the supplied data. That is above the same-industry average market cap of Rs 14,050.04 crore.
How does Pfizer compare with pharma peers on valuation?
Ans. Pfizer’s P/E of 28.59 is lower than Sun Pharma’s 37.69, Divi’s 84.45, Torrent Pharma’s 85.68 and Cipla’s 33.46, but higher than Zydus Lifesciences at 25.53. Its P/B ratio is 4.77x.
What should investors monitor next in Pfizer stock news?
Ans. Investors may track whether the stock stabilises after today’s fall, how it behaves relative to the day’s low of Rs 4,410 and open-high level of Rs 4,599.95, and whether valuation and profitability continue to compare favourably with industry and peer.
